Form 8-K - Current report:
SEC Accession No. 0001193125-25-121714
Filing Date
2025-05-16
Accepted
2025-05-16 16:26:52
Documents
13
Period of Report
2025-05-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d933150d8k.htm   iXBRL 8-K 25791
  Complete submission text file 0001193125-25-121714.txt   148147

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nmra-20250514.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20250514_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20250514_pre.xml EX-101.PRE 11266
15 EXTRACTED XBRL INSTANCE DOCUMENT d933150d8k_htm.xml XML 3639
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 25959698
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)